ProKidney Corp.
Nikhil Pereira-Kamath has a diverse work experience spanning various roles and industries. Nikhil is currently the Chief Business Officer at ProKidney Corp., where they are responsible for developing the organization's long-range strategic plans and leading efforts in business development and innovative solutions. Prior to this, Nikhil was the Executive Chairman and Co-Founder of Africa Healthcare Network, a dialysis chain in Sub-Saharan Africa. Nikhil also worked as an Endeavor Entrepreneur and a Venture Partner at P1 Ventures. Additionally, they have experience in the investment banking sector, having worked as an Analyst at Morgan Stanley and as an Associate at Berkshire Partners. Nikhil was also involved with the International Society of Nephrology's Emerging Leaders Program and worked as a Summer Research Analyst at Oxford Bioscience Partners. Overall, Nikhil's work experience demonstrates their expertise in business development, healthcare, investment banking, and entrepreneurship.
Nikhil Pereira-Kamath completed a Bachelor of Arts degree in Economics and Finance from Princeton University between 2006 and 2010. Nikhil then pursued a Master of Business Administration (M.B.A.) from Harvard Business School, which they are predicted to finish in 2023. Additionally, they hold a FINRA Series 79 certification, although specific details regarding the institution and year of obtaining the certification are not available.
This person is not in any offices
ProKidney Corp.
ProKidney (Nasdaq: PROK), a pioneer in the treatment of CKD through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney’s lead product candidate, REACT™ (Renal Autologous Cell Therapy), is a first-of-its-kind, patented disease-modifying autologous cellular therapy with the potential to not only slow and stabilize the progression of CKD, but in some cases potentially drive meaningful improvement in kidney function. Late-stage CKD, Stage 3b - 4, is a key target for REACT™ therapy. REACT™ has received Regenerative Medicine Advanced Therapy (RMAT) designation, as well as FDA and EMA guidance, supporting its ongoing Phase 3 clinical program, which launched in January 2022. For more information, visit www.prokidney.com.